Using ligands to target cancer cells.
Laboratory of Nanomedicine and Biomaterials, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Omid C
OC
Farokhzad
D000954:Antigens, Surface / Q000235:genetics; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017321:Clinical Trials, Phase I as Topic; D000077143:Docetaxel; D004337:Drug Carriers / Q000138:chemical synthesis / Q000494:pharmacology*; D004339:Drug Compounding; D042783:Endothelial Cells / Q000187:drug effects / Q000473:pathology; D043425:Glutamate Carboxypeptidase II / Q000037:antagonists & inhibitors / Q000235:genetics; D006801:Humans; D056656:Lab-On-A-Chip Devices; D008024:Ligands; D008297:Male; D050997:Nanomedicine; D053758:Nanoparticles / Q000737:chemistry / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D034622:RNA Interference; D043823:Taxoids / Q000494:pharmacology*
D000954:Antigens, Surface; D000970:Antineoplastic Agents; D004337:Drug Carriers; D008024:Ligands; D043823:Taxoids; D000077143:Docetaxel; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II